Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Payables (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Payables for 10 consecutive years, with $13.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 13.13% to $13.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.9 million, a 13.13% increase, with the full-year FY2025 number at $13.9 million, up 13.13% from a year prior.
  • Payables was $13.9 million for Q4 2025 at Rhythm Pharmaceuticals, up from $13.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $16.0 million in Q2 2025 to a low of $3.8 million in Q3 2023.
  • A 5-year average of $8.4 million and a median of $6.8 million in 2022 define the central range for Payables.
  • Peak YoY movement for Payables: tumbled 45.81% in 2024, then surged 251.79% in 2025.
  • Rhythm Pharmaceuticals' Payables stood at $5.7 million in 2021, then decreased by 16.38% to $4.8 million in 2022, then grew by 1.83% to $4.9 million in 2023, then surged by 152.36% to $12.3 million in 2024, then increased by 13.13% to $13.9 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Payables are $13.9 million (Q4 2025), $13.6 million (Q3 2025), and $16.0 million (Q2 2025).